2 Stocks I’d Stay Far Away From Today

MedMen Enterprises Inc (CNSX:MMEN) has declined by 40% in the past year, and that’s still not enough to make the stock a good buy.

| More on:
Businessman pulling out wooden brick from toppling stack

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

We’ve seen some great deals appear on the markets lately amid a lot of selling that’s been taking place. However, some stocks remain unappealing buys today, even if they were to continue falling. Below are two stocks that I couldn’t be convinced to buy anytime soon.

MedMen Enterprises (CNSX:MMEN) looked like a very appealing buy even a year ago. The stock was trading at more than $9 a share back in October and was looking like it could be a real big player in the cannabis industry south of the border. Its Apple-like stores have been able to draw in many customers, and it has proven to be a very popular brand.

Since then, however, we’ve seen a lot of changes both in the industry and in MedMen as well. We’ve seen some big multi-state operators proving to be formidable opponents for MedMen, including the biggest, Curaleaf Holdings. The battle for market share has proven to be intense in the industry, and it shows no signs of slowing down.

Although MedMen has been able to generate more than $100 million in sales over the trailing 12 months, its losses have continued to mount, and the company has been burning through lots of cash along the way. The problem could become worse, as MedMen recently announced it would be offering home delivery in California, which could become another costly venture.

The stock may appear cheap, trading at around four times its sales, but the reality is that the stock is a very risky one that could continue to fall even further. With many key people leaving the organization in the past year and all sorts of problems facing the company, it may even be one of the worst cannabis stocks to buy today.

Restaurant Brands International (TSX:QSR)(NYSE:QSR) is another stock I’d avoid, but not for the same reasons as MedMen. Restaurant Brands is a quality stock, but it’s just not one that I’d consider buying — not anytime soon. It pays a dividend, has some great restaurant chains in its portfolio, and posts a profit. It looks like a great stock from afar, but there are multiple reasons I wouldn’t invest in it.

First and foremost, it’s a very expensive stock to own. At more than 40 times earnings and around 14 times its book value, investors that buy the stock today are paying a significant premium for it. That would be okay if the company were achieving incredible growth, but that hasn’t been the case. Same-store sales growth numbers haven’t been strong at all, especially at Tim Hortons.

Restaurant Brands also has a lot of debt on its books, and that could continue to get worse, especially as it continues to expand its brands across the globe. For investors, it could be a concern, because if the company needs to raise additional cash, it might have to start coming out of new share issues and that would dilute existing shareholders.

The stock could be a good buy under the right circumstances, but it would have to be a lot cheaper, and its debt would have to come down significantly. Otherwise, there’s simply too much risk here for Restaurant Brands to be an appealing buy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. David Gardner owns shares of Apple. The Motley Fool owns shares of Apple and RESTAURANT BRANDS INTERNATIONAL INC and has the following options: short October 2019 $82 calls on RESTAURANT BRANDS INTERNATIONAL INC, short January 2020 $155 calls on Apple, long January 2020 $150 calls on Apple, short January 2020 $155 calls on Apple, and long January 2020 $150 calls on Apple.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »